Clinical Trials on Polycystic Ovarian Disease in Finland

Total 8317 results

Oulu University Hospital
Roche Diagnostics

Recruiting

AMH for the Identification of PCOM in PCOS Diagnosis (HARMONIA)

Polycystic Ovary Syndrome

Finland
University of Oulu
Pfizer

Completed

The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women

Polycystic Ovary Syndrome

Finland
University of Oulu

Unknown

Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary Syndrome

Adverse Effect of Oral Contraceptives, Sequela

Finland
Ferring Pharmaceuticals

Completed

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

Infertility | Polycystic Ovarian Syndrome

United States
University of Oulu
University of Turku; University of Helsinki; Tampere University; University of...

Completed

The Effects of Metformin on Pregnancy and Miscarriage Rates in Polycystic Ovary Syndrome (PCOS)

Toxemia | Polycystic Ovary Syndrome | Infertility | Miscarriage | Gestational Diabetes

Finland
Tampere University Hospital
University of Helsinki; Tampere University

Active, not recruiting

Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer (CHEMOVA)

Ovarian Cancer

Finland
Turku University Hospital

Recruiting

Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia (OVANOX)

Hypoxia | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Carcinoma

Finland
Turku University Hospital

Active, not recruiting

Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (Mupet)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Finland
University of Helsinki
Helsinki University Central Hospital

Recruiting

Systems Oncology Approach to Optimize Ovarian Cancer Treatment (ONCOSYS-OVA)

Ovarian Cancer

Finland
Nordic Society of Gynaecological Oncology - Clinical...

Completed

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Ovarian Epithelial Cancer Recurrent

Denmark, Finland, Norway
Oulu University Hospital
University of Oulu; Academy of Finland; Roche Diagnostics; PerkinElmer, Inc.; Sigrid... and other collaborators

Recruiting

PEPPI Study: Identification of Women at Risk for Placental Dysfunction

Cardiovascular Diseases | Polycystic Ovary Syndrome | Iron-deficiency | Pre-Eclampsia | Intrauterine Growth Restriction | Hypertensive Disorder of Pregnancy | Proteinuria in Pregnancy

Finland
Kancera AB
LINK Medical Research AB; CRST Oy; Q&Q Labs AB

Completed

Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145

Ovarian Cancer

Finland
Tampere University Hospital
University of Turku; University of Helsinki; Tampere University; Aalto University

Recruiting

Measuring Oncological Value of Exercise and Statin (MOVES)

Kidney Cancer | Breast Cancer | Metastatic Renal Cell Carcinoma | Ovarian Cancer | Prostate Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Ovarian Cancer | Metastatic Renal Cancer | Metastatic Kidney Cancer | Metastatic Ovary Cancer

Finland
Nordic Society of Gynaecological Oncology - Clinical...

Withdrawn

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Ovarian Cancer

Norway, Denmark, Finland
Women and Infants Hospital of Rhode Island
Ortho Biotech, Inc.

Terminated

Doxil and Gemcitabine in Recurrent Ovarian Cancer

Ovarian Carcinoma

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Nausea and Vomiting | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
Nordic Society of Gynaecological Oncology - Clinical...
European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic...

Completed

Trial in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

Norway, Finland, Denmark
Women and Infants Hospital of Rhode Island

Completed

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
Fujirebio Diagnostics, Inc.

Completed

Risk of Ovarian Cancer in Patients With a Pelvic Mass

Ovarian Cancer

United States
Kuopio University Hospital

Completed

Implementation of 23 Hour Surgery Model in a Tertiary Hospital (Herko)

Ovarian Cysts | Shoulder Impingement Syndrome | Appendicitis | Cholecystolithiasis | Laparoscopy | Ambulatory Surgical Procedures | Neurosurgery | Ambulatory Surgery | Gynecologic Surgical Procedures

Finland
Women and Infants Hospital of Rhode Island

Terminated

Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.

Breast Cancer | Ovarian Cancer

United States
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, Hungary, United Kingdom, Australia, Bulgaria, Poland, Turkey
Women and Infants Hospital of Rhode Island
Amgen

Terminated

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Turku University Hospital
University of Helsinki

Recruiting

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC (DECIDER)

High Grade Serous Carcinoma | High Grade Ovarian Serous Adenocarcinoma

Finland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Ludwig Institute for Cancer Research
Celgene; Cancer Research Institute, New York City; MedImmune LLC

Completed

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Ovarian Cancer

United States, Switzerland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Brown University
Pfizer; Lifespan

Terminated

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Neutropenia | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Infectious Disorder

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
Astellas Pharma Global Development, Inc.

Completed

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Ovarian Cancer | NSCLC | Solid Tumors | ESCC

United States
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
Onxeo

Completed

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Epithelial Ovarian Cancer

United States, Denmark, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
Fujirebio Diagnostics, Inc.
Advanced Clinical Research Services, LLC; ReSearch Pharmaceutical Services,...

Completed

Ovarian Cancer Risk Estimation in Patients With Pelvic Mass

Ovarian Cancer | Adnexal Mass

United States
Elucida Oncology

Active, not recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Golfers Against Cancer

Recruiting

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Ovarian Cancer

United States
National Human Genome Research Institute (NHGRI)

Completed

Microarray Analysis for Human Genetic Disease

Melanoma | Breast Neoplasm | Ovarian Neoplasm | Hereditary Neoplastic Syndrome

United States, Finland, Iceland, Sweden
AstraZeneca
Parexel; Covance; Iqvia Pty Ltd; Theradex; Myriad Genetics, Inc.

Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)

Non-Germline BRCA Mutated Ovarian Cancer

Italy, Spain, Sweden, Canada, Czechia, Poland, United Kingdom, Israel, Austria, Belgium, Switzerland, Netherlands, Bulgaria, Finland, Norway, Denmark, Slovenia, Portugal
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
Tesaro, Inc.
Gynecologic Oncology Group

Terminated

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)

Ovarian Neoplasms

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Nektar Therapeutics

Completed

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

Ovarian Cancer | Tumor

United States, Belgium, United Kingdom

Clinical Trials on Polycystic Ovarian Disease in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations